Glaxo seeks to counter drug fears
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO, the pharmaceuticals group, yesterday attempted to soothe fears about the side-effects of its migraine drug Imigran, publishing a new study that suggests that it does not endanger heart function, writes Patrick Hosking.
The drug, launched last year, could yield annual sales of pounds 500m within three years, analysts say. However, some patients have reported chest pains after taking it.
Chest pains occurred in 3-5 per cent of 10,500 patients in the new study. But tests on 8,500 at or shortly after treatment showed no evidence of ischaemia, a decrease in blood supply to the heart, which can be a warning of a heart attack.
Glaxo officials said they did not know the cause of the chest pain but were exploring non-heart functions such as the lungs.
Didier Cowling, Nomura analyst, said the study did little more than confirm what was already known. It might reassure doctors prescribing the drug.
Glaxo shares fell 14p to 750p in a declining market.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments